Health authorities in the United States have urgently recalled the commonly used blood pressure medication “Ziac” from the market. The decision was made over concerns that some batches of the drug may have been affected by cross contamination with another medication.
According to the U.S. Food and Drug Administration (FDA), the well-known pharmaceutical company Glenmark Pharmaceuticals conducted preliminary tests on its own, which surprisingly detected particles of the cholesterol lowering drug “Ezetimibe” in the medication.
Ziac contains bisoprolol fumarate and hydrochlorothiazide and is used for blood pressure, heart rhythm, and sometimes heart related conditions. Experts say that although Ezetimibe is itself a certified medication, its unintended presence can disrupt a patient’s ongoing medication schedule, making timely recall essential.
The FDA has classified this recall as a “Class III recall,” which is considered a relatively low risk category. This classification usually applies to situations where there is minimal chance of serious harm to the patient, but the recall is considered necessary as a precaution.
Officials stated that so far, no reports have emerged indicating any direct negative effects on patients due to this contamination. However, health experts have advised citizens using Ziac to check the batch number of their medicine and consult their doctor or pharmacist if needed.
Glenmark Pharmaceuticals has assured that it is investigating the matter with full transparency and taking additional safety measures to prevent such situations in the future. The company says that patient safety is its top priority.
